fda approval tirzepatide for Zepbound: FSU researcher available for context on newly approved weight loss treatment RxConnection | FDA Approves New

Subpopulation analysis in STEP 1, which involved only non-diabetic obese patients, revealed that weekly GLP1/GIP medication eliminated 6.99 kg and 0.27 kg more total and visceral fat mass, respectively, than placebo as measured by dual emission X-ray absorptiometry

Its a process, but when you start to see results, it all feels worthwhile

protocol v3.0 published with eligibility, contraindications, 0.252.4 mg titration with 4-week minimum, lab gate, dose-reduction triggers, follow-up at week 4/12/26/52

Equipment required B12 ampoule 2.5ml syringe green needle blue needle alcohol swab cotton wool sharps box Step-by-step guide Step 1